PYXS News and Press, Pyxis Oncology Inc. From 12/01/22

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity in patients with select solid tumors ...

Pyxis Oncology press release ( NASDAQ: PYXS ): Q3 GAAP EPS of -$0.85 misses by $0.03 . As of November 1, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 35,097,256. For further details see: Pyxis Oncology GAAP EPS of -$0.85 misses...

Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to certain licensed targets ; Initial multi-target sublicense deal execute...

Pyxis Oncology press release ( NASDAQ: PYXS ): Q2 GAAP EPS of -$0.79 beats by $0.06 . Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to f...

• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a senior biotech executive with extensive experience in drug development, to its Board ...

CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, reported on July 1, 2022 that Pyxis Oncology’s Board of Directors granted restricted stock u...

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discov...

The following slide deck was published by Pyxis Oncology, Inc. in conjunction with this event. For further details see: Pyxis Oncology (PYXS) Investor Presentation - Slideshow

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, an...

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Co...